Balversa is an oral kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible fibroblast growth factor receptor 3 (FGFR3) or FGFR2 genetic alterations and has progressed during or following at least 1 line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
If you have a Hayes login, click here to view the full report on the Knowledge Center.